Paediatric systemic lupus erythematosus: Prognostic impact of antiphospholipid antibodies

Rheumatology

Volumn 47, Issue 2, 2008, Pages 183-187

  Descloux, Elodie ^a   Durieu, I ^a   Cochat, P ^b   Vital Durand, D ^a   Ninet, J ^b   Fabien, N ^b   Cimaz, R ^b  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

Anti phospholipid antibodies; Paediatric; Prognosis; Systemic lupus erythematosus

Indexed keywords

AZATHIOPRINE; CARDIOLIPIN ANTIBODY; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; LUPUS ANTICOAGULANT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHOSPHOLIPID ANTIBODY;

ADOLESCENT; ADULT; ANTIPHOSPHOLIPID SYNDROME; ANTITHROMBIN DEFICIENCY; ARTICLE; CHILD; CHILD CARE; CONTRACEPTION; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE COURSE; FEMALE; FOLLOW UP; HEART DISEASE; HEMATOLOGIC DISEASE; HUMAN; IMMOBILIZATION; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SKIN DISEASE; SMOKING; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS;

ADOLESCENT; ADULT; ANTIBODIES, ANTIPHOSPHOLIPID; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOGLOBULIN M; INFANT; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PATIENT SELECTION; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 38649104143     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kem335     Document Type: Article

References (46)

1. Tucker LB, Menon S, Schaller JG, Isenberg DA. Adult and childhood onset systemic lupus erythematosus: A comparison of onset, clinical features, serology and outcome. Br J Rheumatol 1995;34:866-72.
2. Font J, Cervera R, Espinosa G et al. Systemic lupus erythematosus (SLE) in childhood: Analysis of clinical and immunologicals findings in 34 patients and comparison with SLE characteristics in adults. Ann Rheum Dis 1998;57:456-9.
3. Rood MJ, ten Cate R, van Suijlekom-Smit LW et al. Childhood-onset systemic lupus erythematosus: Clinical presentation and prognosis in 31 patients. Scand J Rheumatol 1999;28:222-6.
4. Iqbal S, Sher MR, Good RA, Cawkwell GD. Diversity in presenting manifestations of systemic lupus erythematosus in children. J Pediatr 1999;135:500-5.
5. Carreno L, Lopez-Longo FJ, Monteagudo I et al. Immunological and clinical differences between juvenile and adult onset of systemic lupus erythematosus. Lupus 1999;8:287-92.
6. Barron KS, Silverman ED, Gonzales J, Reveille JD. Clinical, serologic, and immunogenetic studies in childhood-onset systemic lupus erythematosus. Arthritis Rheum 1993;36:348-54.
7. Costallat LT, Coimbra AM. Systemic lupus erythematosus: Clinical and laboratory aspects related to age at disease onset. Clin Exp Rheumatol 1994;12:603-7.
8. Cervera R, Abarca-Costalago M, Abramovicz D et al. Systemic lupus erythematosus in Europe at the change of the millennium: Lessons from "Euro-Lupus Project". Autoimmun Rev 2006;5:180-6.
9. Lehman TJ. Long-term outcome of systemic lupus erythematosus in childhood. What is the prognosis? Rheum Dis Clin North Am 1991;17:921-30.
10. Brunner HI, Feldman BM, Bombardier C, Silverman ED. Sensitivity of the Systemic Lupus Erythematosus Disease Activity Index, British Isles Lupus Assessment Group Index, and Systemic Lupus Activity Measure in the evaluation of clinical change in childhood-onset systemic lupus erythematosus. Arthritis Rheum 1999;42:1354-60.
11. Brunner HI, Silverman ED, To T, Bombardier C, Feldman BM. Risk factors for damage in childhood-onset systemic lupus erythematosus: Cumulative disease activity and medication use predict disease damage. Arthritis Rheum 2002;46:436-44.
12. Revelli A, Duarte-Salazar C, Buratti S et al. Assessment of damage in juvenile-onset systemic lupus erythematosus: A multicenter cohort study. Arthritis Rheum 2003;49:501-7.
13. Miettunen PM, Ortiz-Alvarez O, Petty RE et al. Gender and ethnic origin have no effect on longterm outcome of childhood-onset systemic lupus erythematosus. J Rheumatol 2004;31:1650-4.
14. Lilleby V, Flato B, Forre O. Disease duration, hypertension and medication requirements are associated with organ damage in childhood-onsel systemic lupus erythematosus. Clin Exp Rheumatol 2005;23:281-9.
15. Bandeira M, Buratti S, Bartoli M et al. Relationship between damage accrual, disease flares and cumulative drug therapies in juvenile-onset systemic lupus erythematosus. Lupus 2006;15:515-20.
16. Miyakis S, Lockshin MD, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
17. Cervera R, Piette JC, Font J et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002;46:1019-17.
18. Cimaz R, Descloux E. Pediatric antiphospholipid syndrome. Rheum Dis Clin North Am 2006;32:553-73.
19. Ravelli A, Martini A. Antiphospholipid antibody syndrome in pediatric patients. Rheum Dis Clin North Am 1997;23:657-76.
20. Hochberg MC. Updating the American College of Rhoumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
21. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: An update. Thromb Haemost 1995;74:1185-90.
22. Gladman D, Ginzler E, Goldsmith C et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996;39:363-9.
23. Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989;32:1107-18.
24. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The committee on prognosis studies in SLE. Arthritis Rheum 1992;35:630-40.
25. Wada Y, Wada N, Kubo M et al. Twelve cases of systemic lupus erythematosus in boys. Ryumachi 1998;38:496-503.
26. Apenteng T, Kaplan B, Meyers K. Renal outcomes in children with lupus and a family history of autoimmune disease. Lupus 2006;15:65-70.
27. Hagelberg S, Lee Y, Bergman J et al. Longterm followup of childhood lupus nephritis. J Rheumatol 2002;29:2635-42.
28. Avcin T, Ambrozic A, Kuhar M, Kveder T, Rozman B. Anticardiolipin and anti-b2 glycoprotein I antibodies in sera of 61 apparently healthy children at regular preventive visits. Rheumatology 2001;40:565-73.
29. Galli M. Antiphospholipid syndrome: Association between laboratory tests and clinical practice. Pathophysiol Haemost Thromb 2003-2004;33:249-55.
30. Gatterno M, Buoncompagni A, Molinari AC et al. Antiphospholipid antibodies in paediatric systemic lupus erythematosus, juvenile chronic arthritis and overlap syndromes: SLE patients with both lupus anticoagulant and high-titre anticardiolipin antibodies are at risk for clinical manifestations related to the antiphospholipid syndrome. Br J Rheumatol 1995;34:B73-81.
31. Montes de Oca MA, Babron MC, Bletry O et al. Thrombosis in systemic lupus erythematosus: A French collaborative study. Arch Dis Child 199l;66:713-7.
32. Molta C, Meyer O, Dosquet C et al. Childhood-onset systemic lupus erythematosus: Antiphospholipid antibodies in 37 patients and their first degree relatives. Pediatrics 1993;92:849-53.
33. Ravelli A, Caporali R, Di Fuccia G. Anticardiolipin antibodies in pediatric systemic lupus erythematosus. Arch Pediatr Adolesc Med 1994;148:398-402.
34. Seaman DE, Londino V, Kwoh CK, Medsger TA Jr, Manzi S. Antiphospholipid antibodies in pediatric systemic lupus erythematosus. Pediatrics 1995;96:1040-5.
35. Massengill SF, Hedrick C, Ayoub EM, Sleasman JW, Kao KJ. Antiphospholipild antibodies in pediatric lupus nephritis. Am J Kidney Dis 1997;29:355-61.
36. Berube C, Mitchell L, Silverman E et al. The relationship of antiphospholipid antibodies to thromboembolic events in pediatric patients with systemic lupus erythematosus. Pediatr Res 1998;44:351-6.
37. Campos LM, Kiss MH, D'Amico EA, Silva CA. Antiphospholipid antibodies and antiphospholipid syndrome in 57 children and adolescents with systemic lupus erythematosus. Lupus 2003;12:820-6.
38. Male C, Foulon D, Hoogeñdoom H et al. Predictive value of persistent versus transient antiphospholipid antibody subtypes for the risk of thrombotic events in pediatric patients with systemic lupus erythematosus. Blood 2005; 106:4152-8.
39. Shergy WJ, Kredich DW, Pisetsky DS. The relationship of anticardiolipin antibodies to disease manifestations in pediatric systemic lupus erythematosus. J Rheumatol 1988;15:1389-94.
40. Moroni G, Ventura D, Riva P et al. Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis. Am J Kidney Dis 2004;43:28-36.
41. Angelini L, Ravelli A, Caporali R, Rumi V, Nardocci N, Martini A. High prevalencer of antiphospholipid antibodes in children with idiopathic cerebral ischemia. Pediatrics 1994;94:500-3.
42. Kenet G, Sadetzki S, Murad H et al. Factor V Leiden and antiphospholipid antibodies are significant risk factors for ischemic stroke in children. Stroke 2000;31:1283-8.
43. Cimaz R, Meroni PL, Shoenfeld Y. Epilepsy as part of systemic lupus erythematosus and systemic antiphospholipid syndrome (Hughes syndrome). Lupus 2006;15:191-7.
44. Angelini L, Zibordi F, Zorzi G et al. Neurological disorders, other then stroke, associated with antiphospholipid antibodies in childhood. Neuropediatrics 1996;27:149-63.
45. Harel L, Sandborg C, Lee T, Scheven EV. Neuropsychiatric manifestations in pediatric systemic lupus erythematosus and association with antiphospholipid antibodies. J Rheumatol 2006;33:1873-7.
46. International Registry for Pediatric Antiphospholipid Syndrome. http://www.med.ub.es/MIMMUN/FORUM/PEDIATRIC.HTM